Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) and MariMed (OTCMKTS:MRMD – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Profitability
This table compares Maravai LifeSciences and MariMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Maravai LifeSciences | -51.07% | -17.87% | -9.08% |
| MariMed | -7.82% | -5.00% | -1.29% |
Earnings and Valuation
This table compares Maravai LifeSciences and MariMed”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Maravai LifeSciences | $204.73 million | 6.05 | -$130.77 million | ($0.71) | -6.76 |
| MariMed | $159.83 million | 0.19 | -$14.48 million | ($0.03) | -2.60 |
MariMed has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than MariMed, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Maravai LifeSciences and MariMed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Maravai LifeSciences | 1 | 0 | 3 | 0 | 2.50 |
| MariMed | 0 | 2 | 0 | 0 | 2.00 |
Maravai LifeSciences currently has a consensus price target of $5.50, suggesting a potential upside of 14.58%. Given Maravai LifeSciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe Maravai LifeSciences is more favorable than MariMed.
Institutional and Insider Ownership
50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 0.2% of MariMed shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 19.0% of MariMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk & Volatility
Maravai LifeSciences has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, MariMed has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.
Summary
MariMed beats Maravai LifeSciences on 8 of the 14 factors compared between the two stocks.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
About MariMed
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
